Testing how ketones may affect heart benefits in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You have heart failure with reduced pumping (NYHA Class II–III, ejection fraction under 50%)
- You are 18 to 80 years old and your body mass index (BMI) is 23 to 38
- Your recent blood sugar measure (HbA1c) is between 5.5% and 10% and your blood pressure is at or below 145/85
- Your kidney function is enough for the study (eGFR at least 30) and your heart/diabetes medicines and weight are stable
- You can safely get an MRI (no pacemaker or metal fragments) and you don’t have severe claustrophobia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests whether taking a special oral ketone supplement can help people with both heart failure and diabetes. It looks at both short-term and long-term effects on heart function and blood sugar control.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
Hear when a new Type2 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.